SGMT vs. KPTI, VTGN, COYA, AMLX, INCR, PDSB, CTXR, RPTX, SCTL, and NVCT
Should you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Karyopharm Therapeutics (KPTI), Vistagen Therapeutics (VTGN), Coya Therapeutics (COYA), Amylyx Pharmaceuticals (AMLX), InterCure (INCR), PDS Biotechnology (PDSB), Citius Pharmaceuticals (CTXR), Repare Therapeutics (RPTX), Societal CDMO (SCTL), and Nuvectis Pharma (NVCT). These companies are all part of the "pharmaceutical preparations" industry.
Karyopharm Therapeutics (NASDAQ:KPTI) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.
Sagimet Biosciences has lower revenue, but higher earnings than Karyopharm Therapeutics.
Sagimet Biosciences has a net margin of 0.00% compared to Sagimet Biosciences' net margin of -97.99%.
Karyopharm Therapeutics presently has a consensus price target of $4.80, indicating a potential upside of 336.36%. Sagimet Biosciences has a consensus price target of $39.60, indicating a potential upside of 814.55%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than Karyopharm Therapeutics.
In the previous week, Sagimet Biosciences had 8 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 12 mentions for Sagimet Biosciences and 4 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.51 beat Sagimet Biosciences' score of 0.00 indicating that Sagimet Biosciences is being referred to more favorably in the news media.
66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 4.3% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 17.6% of Sagimet Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Karyopharm Therapeutics received 513 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 100.00% of users gave Sagimet Biosciences an outperform vote while only 72.02% of users gave Karyopharm Therapeutics an outperform vote.
Summary
Sagimet Biosciences beats Karyopharm Therapeutics on 12 of the 14 factors compared between the two stocks.
Get Sagimet Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sagimet Biosciences Competitors List
Related Companies and Tools
